Published in final edited form as:

Mol Nutr Food Res. 2012 March ; 56(3): . doi:10.1002/mnfr.201100521.

Tolerance, fermentation, and cytokine expression in healthy aged male C57BL/6J mice fed resistant starch

June Zhou^{1,3}, Michael J. Keenan², Jeffrey Keller¹, Sun Ok Fernandez-Kim¹, Paul J. Pistell¹, Richard T. Tulley², Anne M. Raggio^{1,2}, Li Shen^{1,2}, Hanjie Zhang^{1,2}, Roy J. Martin^{1,2}, and Marc R. Blackman^{3,4}

¹Pennington Biomedical Research Center, Louisiana State University System, Washington DC

²Louisiana State University Agricultural Center, Washington DC

³Research Service, Veterans Affairs Medical Center, Washington DC

⁴George Washington University School of Medicine, Washington DC, USA

Abstract

Health benefits of resistant starch (RS), a dietary fermentable fiber, have been well documented in young, but not in old populations. As the essential step of more comprehensive evaluations of RS on healthy aging, we examined the effects of dietary RS on tolerance, colonic fermentation, and cytokine expression in aged mice. Healthy older (18–20 months) C57BL/6J male mice were fed control, 18% RS, or 36% RS diets for 10 weeks. Body weight gain, body composition, and fat pad weights did not differ among the three groups after 10 weeks, indicating good tolerance of the RS diet. Fermentation indicators (cecum weights, and cecal proglucagon and PYY mRNA expression) were enhanced in a RS dose dependent manner ($P < 0.01$). Serum concentrations of soluble cytokine receptors (sTNF-Rb; sIL-4R; sIL-2R α sVEGFR1; and sRAGE) and TNF α expression (gene and protein) in visceral fat did not differ significantly among groups. Adiponectin protein concentrations, but not gene expression, were greater in epididymal fat of the 36% RS versus control groups ($P < 0.05$). Conclusion: in aged mice, dietary RS is well tolerated, fermented in the colon, and stimulates colonic expression of proglucagon and PYY mRNA, and adiponectin protein in visceral fat.

Keywords

Resistant Starch; GLP-1; Adiponectin; TNF α ; Aging

Resistant starch (RS) is a fermentable dietary fiber used as a carbohydrate source in food. Multiple animal and human studies in young populations have shown that dietary RS improves health indicators associated with aging [1–3], including improving gastrointestinal health [4–6], glucose tolerance and insulin sensitivity [7–11], and bone density [12, 13]. However, the benefits of dietary RS in older populations are not clear.

RS resists digestion in the small intestine and is fermented in the large intestine by gut microflora. Beneficial effects of dietary RS are dose related [14]. Increased dietary RS consumption augments RS fermentation in the large intestine, which may cause gastrointestinal discomfort. Importantly, certain benefits of dietary RS are also associated with its colonic fermentation, such as expression of the gut anti-obesity/diabetic hormones

GLP-1 and PYY, and body fat loss [10, 15, 16]. At the dosages that show benefits, young rodents and humans tolerate fermentation of dietary RS well [4, 9–12, 16–19]. Given that gut microflora are altered with aging [20], fermentation and toleration of dietary RS may also change with aging. Thus, we investigated tolerance, fermentation and tissue and systemic cytokine expression in healthy aged mice fed two dosages of dietary RS.

Fifty healthy male C57BL/6J mice (18–20 months, analogous to 56–65 years of age in humans [21]) were divided into three dietary treatment groups for a 10 week study: control diet, 18% RS diet, or 36% RS diet. Amioca® cornstarch (100% amylopectin) and Type 2 RS, (Hi-maize 260®) were used as starch sources in control and RS diets (for housing and diets details, see Supporting information). All three diets had the same metabolizable energy density and micro/macro-nutrient contents. The protocol was approved by the Animal Care and Use Committees of the Pennington Biomedical Research Center (#419) and the Washington DC VA Medical Center (#01282). Data were analyzed by one way ANOVA followed by an F protected t-test. Data obtained from mice with tumors were not included for statistical analyses.

Colonic fermentation of dietary RS may cause chronic gastrointestinal discomforts and change appetite, food intake and body weight. Thus, we measured body weight changes over a ten week study period as indirect indices of chronic tolerance of dietary RS. Body composition and tissue weights were also recorded as general indicators of tolerance to the RS diets. At week 8, total body fat, free body fluid (body fluids not bound in tissues), and total lean body mass measured by NMR were not differ among groups (Supporting information). At the end of the study, total abdominal fat was calculated as the sum of the epididymal, perirenal, and retroperitoneal fat pads. Percentages of body fat were calculated as the total abdominal fat divided by the disemboweled body weights (obtained by subtracting the full GI weight from the whole body weight). Disemboweled body weight was used here because of the significantly greater GI weight in RS fed mice. RS and control diets fed mice gained similar amounts of body weight, and exhibited similar body compositions, and body fat, liver and spleen weights ($P>0.05$, Table 1). These results suggest that aged mice tolerated the 18% and 36% RS diets well over a ten week study period.

Prior reports demonstrated that when control and RS diets had the same metabolizable energy density, it took at least 12 weeks for RS fed young rodents to lose body fat [15, 16, 22]. Thus, the study duration of 10 weeks allowed us to examine possible changes in body weight and composition that affected by adverse effects of the RS diet, such as chronic GI discomfort. It remains to be determined whether a longer duration of RS ingestion would decrease body fat in old mice.

Fermentation of the RS diet in aged mice was measured at the end of study. Although aging affects certain gut microflora [20], dietary RS is still fermented in the colon/cecum of aged mice. Full GI tract (from proximal stomach to anus) weight, full cecum weight, empty cecum weight and cecal mRNA levels of proglucagon (gene encodes GLP-1) and PYY were used as indicators of cecal fermentation of dietary RS. All these indicators were increased in RS versus control fed mice ($P<0.01$, Figure 1). Moreover, GI and cecal weights, and proglucagon and PYY gene expression increases were all greater in mice fed 36% versus 18% RS diets. Thus, similar to young mice, dietary RS can be fermented in a dose responsive manner in aged mice.

Because age-related perturbations in body composition and metabolic outcomes are often associated with alterations in pro-inflammatory cytokine and adipocytokine activity, we measured selected cytokine or cytokine receptor levels in serum, liver and fat pads as

biomarkers of systemic and tissue inflammation. Serum concentrations of soluble cytokine receptors (sTNF-Rb, sIL-4R, sIL-2R α , sVEGFR1, sRAGE) measured by MILLIPLEX Mouse Soluble Cytokine Receptor Panel did not differ among groups (Supporting information). Similarly, expression of adiponectin, TNF α , IL-6, and leptin mRNA, measured by real time RT-PCR (Taqman® method, Applied Biosystems) in epididymal and retroperitoneal fat and did not differ among groups (data not shown). Adiponectin and TNF α protein concentrations in epididymal fat and liver were determined by ELISA (see Supporting information for details). Adiponectin concentrations in epididymal fat were increased in RS fed mice, with values in mice fed 36% RS greater than those of controls ($P<0.05$). Liver adiponectin and TNF α in epididymal fat or liver were not different among the three treatment groups (Figure 2). Adiponectin and TNF α protein concentrations were not measured in retroperitoneal fat as there was insufficient tissue for the measurements.

The aims of the current study were to examine the effects of chronic dietary RS ingestion on tolerance, fermentation ability, and systemic and tissue cytokine expression in healthy aged mice. We compared two different doses of RS diets with a control diet. In prior studies, 10–35% RS (wt/wt) diets produced health benefits in young animals [10, 11, 15–17, 23–28]. Thus, our results provide useful dosage information that is necessary for various evaluations of dietary RS as a multifaceted nutritional approach to enhance healthy aging.

Additional, two benefits of dietary RS were noted in the aged mice: increased cecal proglucagon expression and increased adiponectin level in visceral fat. Although circulating GLP-1 was not measured due to limited blood volume in current study, the increased cecal proglucagon expression is always associated with increased circulating GLP-1 in young rats [10, 11, 16]. GLP-1 can reverse the age-related decline in glucose tolerance [29] in part by increasing pancreatic insulin, glucose transporter 2 and glucokinase mRNA, suggesting that GLP-1 reverses some of the aging defects that arise in pancreatic beta cells. GLP-1 receptor stimulation also reduces amyloid- β peptide accumulation in animal models of Alzheimer's disease [30]. Lastly, GLP-1 preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinson's disease [31]. Further studies are necessary to determine whether aged mice, like their younger counterparts, would benefit from increased expression of proglucagon by dietary RS.

Of note, plasma adiponectin was not changed by dietary RS in young people [9]. Thus, the increased visceral fat adiponectin may only improve insulin sensitive in visceral fat and is not accompanied by an increase in circulating adiponectin improve in aged mice.

In conclusion, our data suggest that in aged male C57BL/6J mice, dietary RS is well tolerated, is fermented in the colon, stimulates gut proglucagon and PYY expression, and increases adiponectin in visceral fat. Further studies are required to determine the metabolic and other physiologic consequences of RS ingestion in young and old rodents and humans.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by NIH R21 DK073403 to Drs. Roy J. Martin, June Zhou and Michael Keenan; by Pennington Biomedical Research Center intramural funds to Dr. Jeffrey Keller, and by DCVAMC intramural funds to Dr. Marc Blackman. Drs. Roy Martin and Michael Keenan received research funding from National Starch, LLC. This paper was approved for publication by the Director of Louisiana Agricultural Experiment Station as manuscript no. 2011-239-6324.

List of abbreviations

RS	Resistant starch
TNFα	Tumor necrosis factor alpha
GLP-1	Glucagon-like peptide-1
PYY	Peptide YY
NMR	Nuclear magnetic resonance
GI	gastrointestinal
sTNF-Rb	Soluble Tumor Necrosis Factor Receptor Type b
sIL-4R	soluble interleukin 4 receptor
sIL-2Rα	soluble interleukin 2 receptor alpha
sVEGFR1	soluble vascular endothelial growth factor receptor 1
sRAGE	soluble receptor for advanced glycation endproduct

References

- Haralampu S. Resistant starch - a review of the physical properties and biological impact of RS. *Carbohydrates and Polysaccharides*. 2000;285–92.
- Higgins JA. Resistant starch: metabolic effects and potential health benefits. *J AOAC Int*. 2004 May-Jun;87(3):761–8. [PubMed: 15287677]
- Kendall CW, Emam A, Augustin LS, Jenkins DJ. Resistant starches and health. *J AOAC Int*. 2004 May-Jun;87(3):769–74. [PubMed: 15287678]
- Birkett A, Muir J, Phillips J, Jones G, O'Dea K. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. *Am J Clin Nutr*. 1996 May; 63(5):766–72. [PubMed: 8615362]
- Bird AR, Brown IL, Topping DL. Starches, resistant starches, the gut microflora and human health. *Curr Issues Intest Microbiol*. 2000 Mar; 1(1):25–37. [PubMed: 11709851]
- Ahmed R, Segal I, Hassan H. Fermentation of dietary starch in humans. *Am J Gastroenterol*. 2000 Apr; 95(4):1017–20. [PubMed: 10763953]
- Behall KM, Howe JC. Effect of long-term consumption of amylose vs amylopectin starch on metabolic variables in human subjects. *Am J Clin Nutr*. 1995 Feb; 61(2):334–40. [PubMed: 7840071]
- Brennan CS. Dietary fibre, glycaemic response, and diabetes. *Mol Nutr Food Res*. 2005 Jun; 49(6): 560–70. [PubMed: 15926145]
- Johnston KL, Thomas EL, Bell JD, Frost GS, Robertson MD. Resistant starch improves insulin sensitivity in metabolic syndrome. *Diabet Med*. 2010 Apr; 27(4):391–7. [PubMed: 20536509]
- Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. *Am J Physiol Endocrinol Metab*. 2008 Nov; 295(5):E1160–6. [PubMed: 18796545]
- Shen L, Keenan MJ, Raggio A, Williams C, Martin RJ. Dietary-resistant starch improves maternal glycemic control in Goto-Kakizaki rat. *Mol Nutr Food Res*. 2011 Jun 3.
- Tousen Y, Abe F, Ishida T, Uehara M, Ishimi Y. Resistant starch promotes equal production and inhibits tibial bone loss in ovariectomized mice treated with daidzein. *Metabolism*. 2011 May 5.
- Bogden JD, Kemp FW, Huang AE, Shapses SA, Ambia-Sobhan H, Jagpal S, et al. Bone mineral density and content during weight cycling in female rats: effects of dietary amylase-resistant starch. *Nutr Metab (Lond)*. 2008; 5:34. [PubMed: 19036159]
- Penn-Marshall M, Holtzman GI, Barbeau WE. African americans may have to consume more than 12 grams a day of resistant starch to lower their risk for type 2 diabetes. *J Med Food*. Aug; 13(4): 999–1004. [PubMed: 20482275]

15. Zhou J, Martin RJ, Tulley RT, Raggio AM, Shen L, Lissy E, et al. Failure to Ferment Dietary Resistant Starch in Specific Mouse Models of Obesity Results in No Body Fat Loss. *J Agric Food Chem*. 2009 Sep 9.
16. Keenan MJ, Zhou J, McCutcheon KL, Raggio AM, Bateman HG, Todd E, et al. Effects of Resistant Starch, A Non-digestible Fermentable Fiber, on Reducing Body Fat. *Obesity* (Silver Spring). 2006 Sep; 14(9):1523–34. [PubMed: 17030963]
17. Shen L, Keenan MJ, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, et al. Dietary resistant starch increases hypothalamic POMC expression in rats. *Obesity* (Silver Spring). 2009 Jan; 17(1): 40–5. [PubMed: 18948970]
18. Hylla S, Gostner A, Dusel G, Anger H, Bartram HP, Christl SU, et al. Effects of resistant starch on the colon in healthy volunteers: possible implications for cancer prevention. *Am J Clin Nutr*. 1998 Jan; 67(1):136–42. [PubMed: 9440388]
19. Cheng HH, Lai MH. Fermentation of resistant rice starch produces propionate reducing serum and hepatic cholesterol in rats. *J Nutr*. 2000 Aug; 130(8):1991–5. [PubMed: 10917913]
20. Hebuterne X. Gut changes attributed to ageing: effects on intestinal microflora. *Curr Opin Clin Nutr Metab Care*. 2003 Jan; 6(1):49–54. [PubMed: 12496680]
21. Harrison, DE. How we define the life history phases of mice; how they compare with humans Life span as a biomarker. 2011. <http://research.jax.org/faculty/harrison/ger1vLifespan1.html>
22. Pawlak DB, Kushner JA, Ludwig DS. Effects of dietary glycaemic index on adiposity, glucose homeostasis, and plasma lipids in animals. *Lancet*. 2004 Aug-Sep; 364(9436):778–85. [PubMed: 15337404]
23. Bajka BH, Clarke JM, Cobiack L, Topping DL. Butyrylated starch protects colonocyte DNA against dietary protein-induced damage in rats. *Carcinogenesis*. 2008 Nov; 29(11):2169–74. [PubMed: 18684730]
24. de Deckere EA, Kloots WJ, van Amelsvoort JM. Resistant starch decreases serum total cholesterol and triacylglycerol concentrations in rats. *J Nutr*. 1993 Dec; 123(12):2142–51. [PubMed: 8263609]
25. Higgins JA, Brown MA, Storlien LH. Consumption of resistant starch decreases postprandial lipogenesis in white adipose tissue of the rat. *Nutr J*. 2006; 5:25. [PubMed: 16987425]
26. Le Leu RK, Brown IL, Hu Y, Young GP. Effect of resistant starch on genotoxin-induced apoptosis, colonic epithelium, and luminal contents in rats. *Carcinogenesis*. 2003 Aug; 24(8): 1347–52. [PubMed: 12807738]
27. Lopez HW, Levrat-Verny MA, Coudray C, Besson C, Krespine V, Messenger A, et al. Class 2 resistant starches lower plasma and liver lipids and improve mineral retention in rats. *J Nutr*. 2001 Apr; 131(4):1283–9. [PubMed: 11285339]
28. Morita T, Kasaoka S, Ohhashi A, Ikai M, Numasaki Y, Kiriya S. Resistant proteins alter cecal short-chain fatty acid profiles in rats fed high amylose cornstarch. *J Nutr*. 1998 Jul; 128(7):1156–64. [PubMed: 9649600]
29. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh C, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. *J Clin Invest*. 1997 Jun 15; 99(12):2883–9. [PubMed: 9185511]
30. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, et al. GLP-1 Receptor Stimulation Reduces Amyloid-beta Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease. *J Alzheimers Dis*. 2009 Dec 14.
31. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. *Proc Natl Acad Sci U S A*. 2009 Jan 27; 106(4):1285–90. [PubMed: 19164583]

Figure 1.

Fermentation indicators (full GI weight, full cecal weight, empty cecal weight, cecal proglucagon and PYY gene expression) of mice fed control, 18% RS, and 36% RS diet for ten weeks. Tissues were collected by dissection. mRNA was measured by quantitative RT-PCR. Data shown are mean $\pm$ SE (n=13–15 per group) values, and are expressed as fold changes in RS versus control mice. Values with different letters indicate significant differences ($P < 0.01$).

Figure 2.

Adiponectin (A, C) and TNFα (B, D) protein levels in epididymal fat (A, B) and liver (C, D) of aged mice fed control diet, 18% RS, or 36% RS diet for ten weeks. Adiponectin and TNFα concentrations were detected by ELISA. Data shown are mean ± SE (n=12–15 per group) values. Values with different letters indicate significant differences (P<0.05).

Table 1

Body weight, liver, spleen, and fat depot weights in control and RS treatment groups at the end of study. Data shown are mean $\pm$ SE values.

	Control	18% RS	36% RS	P value
Number of mice (beginning)	17	17	16	
Initial Body weights (g)	34.85 $\pm$ 0.69	34.69 $\pm$ 0.43	34.56 $\pm$ 1.08	>0.05
Final Body weights (g)	36.68 $\pm$ 1.18	39.17 $\pm$ 0.73	37.58 $\pm$ 1.14	>0.05
Disemboweled body weights (g)	34.42 $\pm$ 1.18	36.20 $\pm$ 0.73	33.84 $\pm$ 1.13	>0.05
Liver weights (g)	1.59 $\pm$ 0.07	1.90 $\pm$ 0.16	1.62 $\pm$ 0.07	>0.05
Spleen weights (g)	0.113 $\pm$ 0.009	0.168 $\pm$ 0.038	0.112 $\pm$ 0.011	>0.05
Epididymal fat (g)	1.851 $\pm$ 0.187	1.967 $\pm$ 0.163	1.789 $\pm$ 0.182	>0.05
Perirenal fat (g)	0.379 $\pm$ 0.040	0.423 $\pm$ 0.033	0.328 $\pm$ 0.041	>0.05
Retroperitoneal fat (g)	0.568 $\pm$ 0.061	0.589 $\pm$ 0.045	0.507 $\pm$ 0.053	>0.05
Total fat (g)	2.798 $\pm$ 0.280	2.978 $\pm$ 0.236	2.625 $\pm$ 0.266	>0.05
% fat/body weight	7.84 $\pm$ 0.61	8.10 $\pm$ 0.53	7.55 $\pm$ 0.55	>0.05
Number of mice that died during the study	1	1	0	
Number of mice with tumor(s) at the end of study	1	2	1	